{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

A survey to assess the preference and usage of different formulations of Oxcarbazepine (Oxcarbazepine IR/XR, and syrup) in the management of epilepsy.

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire
  1. Approximately how many epilepsy patients do you manage per month in your clinical practice? *

  2. What is the most common age group of epilepsy patients in your practice? *

  3. What is the most prevalent seizure type you encounter in your clinical practice? *

  4. Do you use the 2017 ILAE classification for categorizing seizure types in your clinical practice? *

  5. In your experience, do patients and caregivers demonstrate adequate awareness and understanding of epilepsy and its management? *

  6. What methods do you primarily use to educate patients and caregivers about epilepsy and its management? *
  7. How frequently do you prescribe oxcarbazepine for epilepsy management? *

  8. In what context do you most commonly prescribe oxcarbazepine? *

  9. For which patient population do you most commonly prescribe oxcarbazepine? *

  10. Are there specific patient populations for whom you avoid prescribing oxcarbazepine? If yes, please specify. *

  11. Do you prescribe oxcarbazepine for patients with epilepsy and comorbid psychiatric conditions? *

  12. Which oxcarbazepine formulation do you most frequently prescribe? *

  13. What is your usual starting dose of oxcarbazepine in adult patients with epilepsy? *

  14. What is the typical maintenance dose range of oxcarbazepine you prescribe for epilepsy in adults? *

  15. In which pediatric age group do you most commonly prescribe oxcarbazepine oral suspension? *

  16. Which oxcarbazepine formulation do you prefer for older adults (≥65 years) with epilepsy? *

  17. What is your primary reason for prescribing oxcarbazepine XR over other formulations? *
  18. Do you prefer oxcarbazepine XR over IR for epilepsy management? *

  19. Do you recommend broader use of oxcarbazepine XR over IR for epilepsy management? Why or why not? *
  20. Have you observed differences in patient adherence among oxcarbazepine formulations? *

  21. For patients with poor adherence to oxcarbazepine, which formulation do you recommend? *

  22. What strategies do you recommend to improve patient adherence to oxcarbazepine therapy? *
  23. What is the most common reason for non-adherence to oxcarbazepine therapy in your practice? *
  24. What do you consider to be Oxcarbazepine’s greatest advantage in partial onset seizure management? *
  25. What is the most common side effect reported by your patients on oxcarbazepine? *
  26. How do you manage hyponatremia in patients on oxcarbazepine? *
  27. How often do you counsel patients about oxcarbazepine side effects? *
  28. What is your preferred monitoring interval for patients on oxcarbazepine therapy? *

  29. What percentage of your patients with focal onset seizures achieve seizure freedom with oxcarbazepine (monotherapy or adjunctive)? *

  30. How effective is oxcarbazepine as adjunctive therapy for drug-resistant epilepsy? *

  31. Does adding oxcarbazepine as an adjunctive therapy allow dose reduction of other antiseizure medications (ASMs)? *

  32. How effective is oxcarbazepine in minimizing side effects when used as adjunctive therapy with other ASMs?*

  33. How does oxcarbazepine compare to older ASMs (e.g., valproate, phenytoin) in terms of efficacy for focal onset seizures? *

  34. How would you rate the efficacy and tolerability of oxcarbazepine compared to other ASMs for focal onset seizures? *

  35. Do patients report improvements in quality of life with oxcarbazepine therapy? *

  36. How frequently do you observe seizure recurrence due to missed oxcarbazepine doses? *

  37. What are the primary challenges in managing epilepsy in your clinical setting (e.g., India-specific or other contexts)? *
  38. Which clinical guidelines do you primarily follow when prescribing antiseizure medications for epilepsy and why? *
  39. How often do you collaborate with other specialists (e.g., psychiatrists, neurosurgeons) when managing epilepsy with comorbidities?*

  40. On a scale of 1 to 5 (1 = poor, 5 = excellent), how would you rate your overall satisfaction with oxcarbazepine as a treatment for epilepsy? *